Trial Profile

Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (Arikayce) in Cystic Fibrosis Patients with Chronic Infection due to Pseudomonas aeruginosa

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amikacin (Primary)
Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms CLEAR-110
Sponsors Insmed

Most Recent Events

29 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database record.
15 Feb 2015 Protocol has been been amended in treatment table as change of dose of Liposomal Amikacin from 560 mg to 590 mg.
15 Feb 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com